Skip to main content

Aridis Pharmaceuticals Inc. (ARDS)

NASDAQ: ARDS · IEX Real-Time Price · USD
2.39
0.08 (3.46%)
At close: Nov 26, 2021 1:00 PM
2.44
0.05 (2.09%)
After-hours:Nov 26, 2021 1:11 PM EST
Market Cap33.59M
Revenue (ttm)548,000
Net Income (ttm)-43.33M
Shares Out14.05M
EPS (ttm)-3.95
PE Ration/a
Forward PE11.25
Dividendn/a
Ex-Dividend Daten/a
Volume45,063
Open2.51
Previous Close2.31
Day's Range2.27 - 2.49
52-Week Range2.31 - 8.47
Beta0.12
AnalystsBuy
Price Target15.00 (+527.6%)
Earnings DateNov 19, 2021

About ARDS

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginos...

IndustryBiotechnology
IPO DateAug 10, 2018
Employees33
Stock ExchangeNASDAQ
Ticker SymbolARDS
Full Company Profile

Financial Performance

In 2020, ARDS's revenue was $1,000,000, a decrease of -2.15% compared to the previous year's $1.02 million. Losses were -$22.33 million, -24.76% less than in 2019.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for ARDS stock is "Buy." The 12-month stock price forecast is 15.00, which is an increase of 527.62% from the latest price.

Price Target
$15.00
(527.62% upside)
Analyst Consensus: Buy

News

New Strong Sell Stocks for November 15th

ARDS, CNNE, EXK, GP, and IFF have been added to the Zacks Rank #5 (Strong Sell) List on November 15, 2021.

Other symbols:CNNEEXKGPIFF
1 week ago - Zacks Investment Research

Aridis Pharmaceuticals Announces Third Quarter 2021 Results

LOS GATOS, Calif., Nov. 10, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tr...

2 weeks ago - PRNewsWire

ARIDIS PHARMACT (ARDS) Reports Q2 Loss, Misses Revenue Estimates

ARIDIS PHARMACT (ARDS) delivered earnings and revenue surprises of 3.51% and -91.75%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Aridis Pharmaceuticals Announces Second Quarter 2021 Results

LOS GATOS, Calif., Aug. 12, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tr...

3 months ago - PRNewsWire

Analysts Estimate ARIDIS PHARMACT (ARDS) to Report a Decline in Earnings: What to Look Out for

ARIDIS PHARMACT (ARDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Aridis Pharmaceuticals Announces $25 Million Registered Direct Offering Priced at a Premium to Market

LOS GATOS, Calif., Aug. 2, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tre...

3 months ago - PRNewsWire

Aridis Pharmaceuticals' COVID mAb Ranks Among the Top 5 Most Potent COVID-19 mAbs Evaluated by the Coronavirus Immuno...

LOS GATOS, Calif., July 26, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tr...

4 months ago - PRNewsWire

Aridis Pharmaceuticals Announces Exclusive License of Suvratoxumab, a Phase 3-Ready Monoclonal Antibody, from AstraZe...

LOS GATOS, Calif., July 19, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced that it has entered into an exclusive, worldwide licensing agreement with AstraZeneca (LSE/ST...

Other symbols:AZN
4 months ago - PRNewsWire

Aridis' (ARDS) COVID Antibody Combo Neutralizes Delta Variant

Aridis Pharmaceuticals' (ARDS) inhaled COVID-19 dual antibody cocktail treatment, AR-712, binds and neutralizes the Delta variant of the virus. Stock rises in after-hours trading.

4 months ago - Zacks Investment Research

Aridis Pharma's COVID-19 Antibody Neutralizes Delta Variant In Animal Model

Aridis Pharmaceuticals Inc (NASDAQ: ARDS) has announced that its COVID-19 mAb cocktail AR-712 binds and neutralizes the Delta variant of COVID-19 at a highly effective level (~20ng/mL).  Binding analyse...

4 months ago - Benzinga

Aridis Pharmaceuticals COVID mAb AR-712 Neutralizes SARS-CoV-2 Delta Variant

LOS GATOS, Calif., July 12, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tr...

4 months ago - PRNewsWire

Strength Seen in ARIDIS PHARMACT (ARDS): Can Its 10% Jump Turn into More Strength?

ARIDIS PHARMACT (ARDS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more stren...

5 months ago - Zacks Investment Research

Aridis Pharmaceuticals Announces First Quarter 2021 Results

LOS GATOS, Calif., May 11, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tre...

6 months ago - PRNewsWire

CORRECTING and REPLACING Kermode Biotechnologies Announced that it is Actively Engaged in Discovery to Identify the M...

PARAMUS, N.J.--(BUSINESS WIRE)--Kermode Biotechnologies, Inc., announced that it is actively engaged in discovery to identify the mode of transmission and replication for the ASFV.

7 months ago - Business Wire

Kermode Biotechnologies Announced that it is Actively Engaged in Discovery to Identify the Mode of Transmission for t...

PARAMUS, N.J.--(BUSINESS WIRE)--Kermode Biotechnologies, Inc., announced that it is actively engaged in discovery to identify the mode of transmission and replication for the ASFV.

7 months ago - Business Wire

Aridis Pharmaceuticals Announces 2020 Fourth Quarter and Year-End Financial Results and Business Update

LOS GATOS, Calif., March 30, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to t...

7 months ago - PRNewsWire

Aridis Pharmaceuticals Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®

LOS GATOS, Calif., March 26, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to t...

8 months ago - PRNewsWire

Aridis, Kermode Enter In Licensing And Discovery Agreement For Zoonotic Viruses

Aridis Pharmaceuticals Inc (NASDAQ: ARDS) has entered into an out-licensing and product discovery agreement with a privately-held Kermode Biotechnologies Inc. Kermode works on vaccines and mAbs for zoon...

8 months ago - Benzinga

Aridis Pharma To Test Inhaled Antibody Cocktail In COVID-19 Variants

Aridis Pharmaceuticals Inc (NASDAQ: ARDS) has added its inhaled AR-711 monoclonal antibody with a second antibody, AR-713, designed to neutralize newly emerging COVID-19 mutated variants. The company sa...

9 months ago - Benzinga

Aridis Pharmaceuticals Provides Multiple Program Updates Including the Addition of a Second Inhaled Antibody to Neutr...

LOS GATOS, Calif., Feb. 23, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tr...

9 months ago - PRNewsWire

Aridis Pharmaceuticals to Host Fireside Chat with Analysts to Discuss 2021 Outlook for its Lead Programs and Novel mA...

SAN JOSE, Calif., Nov. 24, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tre...

1 year ago - PRNewsWire

Aridis Pharmaceuticals Announces Third Quarter 2020 Results

SAN JOSE, Calif., Nov. 20, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tre...

1 year ago - PRNewsWire

Aridis Pharmaceuticals to Present at the ROTH Capital Partners 2020 MedTech Innovation Forum on a COVID-19 Panel

SAN JOSE, Calif., Oct. 27, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tre...

1 year ago - PRNewsWire

Aridis Pharmaceuticals Reports Positive Preclinical Efficacy Data of a Highly Effective Inhaled Treatment Supporting ...

SAN JOSE, Calif., Oct. 19, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tre...

1 year ago - PRNewsWire

Aridis Pharmaceuticals Announces $8.5 Million Registered Direct Offering

SAN JOSE, Calif., Oct. 14, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (the "Company"), a biopharmaceutical company focused on the discovery and development of novel anti-infective ...

1 year ago - PRNewsWire